| Literature DB >> 25793199 |
Marta Pokrywczynska1, Iga Gubanska2, Gerard Drewa3, Tomasz Drewa4.
Abstract
Construction of the urinary bladder de novo using tissue engineering technologies is the "holy grail" of reconstructive urology. The search for the ideal biomaterial for urinary bladder reconstruction has been ongoing for decades. One of the most promising biomaterials for this purpose seems to be bladder acellular matrix (BAM). In this review we determine the most important factors, which may affect biological and physical properties of BAM and its regeneration potential in tissue engineered urinary bladder. We also point out the directions in modification of BAM, which include incorporation of exogenous growth factors into the BAM structure. Finally, we discuss the results of the urinary bladder regeneration with cell seeded BAM.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25793199 PMCID: PMC4352424 DOI: 10.1155/2015/613439
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Agents used in urinary bladder acellular matrix preparation.
| Treatment | Main role | Example | Advantages | Disadvantages | |
|---|---|---|---|---|---|
| Mechanical | Force | Removal of tissue layers | Scrapping with the use of the scalpel | Some tissues like bladder and intestinal submucosa have natural planes of dissection and therefore mechanical force can be used to delaminate the tissue layers | Not all tissues can be mechanically treated, because it can disturb the ECM structure |
|
| |||||
| Physical | Temperature | Cell membrane lysis | Freezing cycles | Effective when combined with full decellularization protocol | Applied alone, would not remove cells completely |
| Pressure | Hydrostatic pressure | Effective for tissues which do not have densely organized ECM, such as liver and lungs | Used alone, would not completely remove the cells | ||
|
| |||||
| Chemical | Acids and alkalis | Protein denaturation, | Acetic acid, | Effective | Not selective, |
| Hypertonic/hypotonic solutions | Cell disruption by the osmotic shock, disruption of DNA-protein interaction | Tris/HCl | Efficient | Do not effectively remove the cellular residues | |
| Ionic/nonionic detergents | Destroy DNA-protein interactions, lipids, and lipoproteins | Triton X-100 | Effective, destroy lipid-lipid and lipid-protein interaction but keep protein-protein interactions | Possible protein denaturation, loss of GAGs, laminin, and fibronectin | |
| solvents | Dehydratation | Alcohol, | Effective | Possible ECM constituent destruction | |
|
| |||||
| Enzymatic | Enzymes | Cells rupture | Trypsin, | Targets the residues of nucleic acids | May remain in the tissue with unknown amount and intensify the immune response of the host tissues |
ECM: extracellular matrix; SDS: sodium dodecyl sulphate; GAGs: glycosaminoglycans.
Growth factors incorporated with bladder acellular matrix and their effects on urinary bladder regeneration.
|
Author, year | Growth factor | Growth factor incorporation technique | Experimental model | Urinary bladder regeneration | |
|---|---|---|---|---|---|
| BAM | BAM + exogenous growth | ||||
| Kanematsu et al. 2003 [ | bFGF | Reswelling of the freeze-dried or not-freeze-dried BAM in PBS containing the bFGF radiolabeled with Na125I by chloramine T. | Rat | (i) Graft shrinkage, | (i) Graft shrinkage was reduced (bFGF dose dependent manner) in BAM + bFGF compared to BAM group at 4 weeks postoperatively, |
|
| |||||
| Youssif et al. 2005 [ | VEGF | Incubation of BAM for 12 hours at 37°C in solution containing VEGF, additionally before implantation of the VEGF solution was injected into the 4 areas of the BAM | Rat | (i) No significant differences in bladder capacity, compliance, and intravesical pressure at 8 weeks postoperatively between BAM and BAM + VEGF groups, | (i) Increased neovascularity in BAM + VEGF group compared to BAM group at all points of observation (2, 4, 8, and 12 weeks), |
|
| |||||
| Loai et al. 2010 [ | VEGF | Lyophilized BAM was rehydrated in HA, dehydrated in ethanol, lyophilized for the second time, and then rehydrated in VEGF solution | Pig | (i) Poor organization of smooth muscle fibers in peripheral and central areas of the graft in BAM-HA and BAM groups at 10 weeks postoperatively, | (i) Increased recellularization in BAM-HA-VEGF group compared to BAM-HA and BAM groups, |
|
| |||||
| Kikuno et al. 2009 [ | NGF and VEGF | NGF and VEGF were injected into the 4 points of the bladder submucosa | Rat | (i) Urothelium covered completely the luminal surface of implanted BAM in all groups, | (i) Bladder capacity and compliance were much higher in BAM + NGF + VEGF group compared with BAM + NGF, BAM + VEGF or BAM groups, |
BAM, bladder acellular matrix; bFGF, basic fibroblast growth factor; HA, hyaluronic acid; NGF, nerve growth factor, PGP 9.5, protein gene product 9.5; PBS, phosphate buffered saline; VEGF, vascular endothelial growth factor.
Stem cell types seeded on bladder acellular matrix and their effects on urinary bladder regeneration.
| Author, year [Reference no.] | Cells type | Experimental model | Urinary bladder regeneration | |
|---|---|---|---|---|
| BAM seeded with cells | Unseeded BAM | |||
| Drewa et al. 2009 | Hair follicle stem cells | Rat | (i) All animals survived the observation period, | (i) Unexpected deaths due to the leakage and pyuria in two animals (22%), |
|
| ||||
| Zhu et al. 2010 | Adipose derived stem cells | Rabbit | (i) All animals survived the observation period, | (i) One animal (8%) died due to infection secondary to bladder leakage, |
|
| ||||
| Yuan et al. 2013 | Human umbilical mesenchymal stem cells | Dog | (i) All animals survived the observation period, | (i) All animals survived the observation period, |
|
| ||||
| Pokrywczynska et al. 2013 [ | Bone marrow mesenchymal stem cells | Rat | (i) All animals survived the observation period, | (i) All animals survived the observation period, |
|
| ||||
| Leite et al. 2014 [ | Bone marrow mesenchymal stem cells | Rat | (i) No reduction of inflammation over time (7–28 days after bladder augmentation), | (i) No reduction of inflammation over time (7–28 days after bladder augmentation), |
BAM: bladder acellular matrix.